Renal dysfunction and ischemic heart disease mortality in a hypertensive population

Journal of Hypertension

Volumn 23, Issue 10, 2005, Pages 1809-1816

  Hailpern, Susan M ^a   Cohen, Hillel W ^a   Alderman, Michael H ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Glomerular filtration rate; Hypertension; Ischemic heart disease; Renal dysfunction

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; UNITED STATES;

EID: 29244458138     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000183120.92455.2a     Document Type: Article

References (51)

1. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999; 56:2214-2219.
2. Garg AX, Clark WF, Haynes RB, House AA. Moderate renal insufficiency and the risk of cardiovascular mortality: Results from the NHANES I. Kidney Int 2002; 61:1486-1494.
3. Muntner P, He J, Hamm L, Loria C, Whelton PK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002; 13:745-753.
4. Henry RM, Kostense PJ, Bos G, Dekker JM, Nijpels G, Heine RJ, et al. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int 2002; 62:1402-1407.
5. Fried LF, Shlipak MG, Crump C, Bleyer AJ, Gottdiener JS, Kronmal RA, et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 2003; 41:1364-1372.
6. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41:47-55.
7. Wachtell K, Isben H, Olsen MH, Borch-Johnsen K, Lindholm LH, Morgenson CE, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Ann Int Med 2003; 139:901-906.
8. Rahman M, Brown CD, Coresh J, Davis BR, Eckfeldt JH, Kopyt N, et al., and Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. The prevalence of reduced glomerular filtration rate in older hypertensive patients and its association with cardiovascular disease: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Arch Int Med 2004; 164:969-976.
9. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-1305.
10. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351:1285-1295.
11. Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, Schneider KA, The Hypertension Detection and Follow-Up Program Cooperative Group. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. results from the Hypertension Detection and Follow-Up Program. Hypertension 1989; 13(suppl 5):180-193.
12. Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, Zanchetti A. Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) Study. J Am Soc Nephrol 2001; 12:218-225.
13. Schillaci G, Reboldi G, Verdecchia P. High-normal serum creatinine concentration is a predictor of cardiovascular risk in essential hypertension. Arch Intern Med 2001; 161:886-891.
14. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE Randomized Trial. Ann Intern Med 2001; 134:629-636.
15. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999; 19:1992-1997.
16. Flack JM, Neaton JD, Daniels B, Esunge P. Ethnicity and renal disease: Lessons from the Multiple Risk Factor Intervention Trial and the Treatment of Mild Hypertension Study. Am J Kidney Dis 1993; 21 (suppl 1):31-40.
17. De Leeuw PW, Thijs L, Birkenhager WH, Voyaki SM, Efstratopoulos AD, Fagard RH, et al. Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the Syst-Eur trial. J Am Soc Nephrol 2002; 13:2213-2222.
18. Jungers P, Massy ZA, Khoa TN, Fumeron C, Labrunie M, Lacour B, et al. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: A prospective study. Nephrol Dial Transplant 1997; 12:2597-2602.
19. Gibson MC, Pinto DS, Murphy SA, Moffow DA, Hobbach HP, Wivott SD, et al., and TIMI Study Group. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol 2003; 42:1535-1543.
20. Wannamethee SG, Shaper AG, Perry IJ. Serum creatinine concentration and risk of cardiovascular disease: A possible marker for increased risk of stroke. Stroke 1997; 28:557-563.
21. Alderman MH, Cohen H, Madhavan S, Kivlighn S. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999; 34:144-150.
22. Alderman MH, Ooi WL, Madhavan S, Cohen H. Blood pressure reactivity predicts myocardial infarction among treated hypertensive patients. J Clin Epidemiol 1990; 43:859-866.
23. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324:1098-1104.
24. Alderman MH, Cohen H, Madhavan S. Distribution and determinants of cardiovascular events during 20 years of successful antihypertensive treatment. J Hypertens 1998; 16:761-769.
25. Cohen HW, Madhavan S, Alderman MH. History of treatment for depression: risk factor for myocardial infarction in hypertensive patients. Psychosom Med 2001; 63:203-209.
26. Cohen HW, Alderman MH. Low sodium diet after DASH: Has the situation changed? Dietary approaches to stop hypertension. Curr Hypertens Rep 2002; 4:329-332.
27. Cohen HW, Hailpern SM, Alderman MH. Glucose-cholesterol interaction magnifies CHD risk for hypertensive patients. Hypertension 2004; 43:983-987.
28. Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: Association with use of tricyclic agents. Am J Med 2000; 108:2-8.
29. Joint National Committee on Detection Evaluation and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Int Med 1993; 153:154-183.
30. National Center for Health Statistics. National Center for Health Statistics: What Is the NDI? US Department of Health and Human Services - Centers for Disease Control and Prevention. Available at http://www.cdc.gov/ nchs/r&d/ndi/what_is_ndi.htm (accessed 19 January 2004).
31. National Centers for Health Statistics. International classification of diseases (ICD-9-CM) 9th revision, clinical modification. 5th ed. Ann Arbor: Commission on Professional and Hospital Activities; 1998.
32. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
33. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002; 39(suppl 2):246.
34. Stata. Stata Corporation 8.0/SE. College Station, Texas: Stata Press; 2003.
35. Segura J, Campo C, Ruilope LM. Chronic kidney disease and global cardiovascular risk in essential hypertension. Minerva Med 2004; 95:375.
36. Coladonato J, Klassen P, Owen WF Jr. Perception versus reality of the burden of chronic kidney disease in the United States. J Am Soc Nephrol 2002; 13:1686-1688.
37. Tracy RE, Malcom GT, Oalmann MC, Newman WP III, Guzman MA. Nephrosclerosis, glycohemoglobin, cholesterol, and smoking in subjects dying of coronary heart disease. Mod Pathol 1994; 7:301-309.
38. Tracy RE, Strong JP, Newman WP III, Malcom GT, Oalmann MC, Guzman MA. Renovasculopathies of nephrosclerosis in relation to atherosclerosis at ages 25 to 54 years. Kidney Int 1996; 49:564-570.
39. Rahman M, Brown CD, Coresh J, Davis BR, Eckfeldt JH, Kopyt N, et al. The prevalence of reduced glomerular filtration rate in older hypertensive patients and its association with cardiovascular disease. Arch Intern Med 2004; 164:969-976.
40. Muntner P, Hamm L, Kusek JW, Chen J, Whelton PK, He J. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 2004; 140:9-17.
41. Bostom AG, Shemin D, Verhoef P, Nadeau MR, Jacques PF, Selhub J, et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients, a prospective study. Arterioscler Thromb Vasc Biol 1997; 17:2554-2558.
42. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Circulation 2000; 102:1085.
43. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis CE. Lipoprotein(a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 1994; 271:1003.
44. Kwiterovich PO Jr, Coresh J, Smith HH, Bachorik PS, Derby CA, Pearson TA. Comparison of the plasma levels of apolipoproteins B and A-1, and other risk factors in men and women with premature coronary artery disease. Am J Cardiol 1992; 69:1015-1021.
45. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies. JAMA 1998; 279:1477-1482.
46. Shlipak MG, Fried LF, Cushman WC, Manolio TA, Peterson D, Stehman-Breen C, et al. Cardiovascular mortality risk in chronic kidney disease. JAMA 2005; 293:1737-1745.
47. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: A new paradigm. Am J Kidney Dis 2000; 35(suppl 1):S117-S131.
48. Stenvinkel P, Lindholm B, Heimburger M, Heimburger O. Elevated serum levels of soluble adhesion molecules predict death in pre-dialysis patients: association with malnutrition, inflammation, and cardiovascular disease. Nephrol Dial Transplant 2000; 15:1624-1630.
49. Jungers P. Screening for renal insufficiency: Is it worth while? Is it feasible?. Nephrol Dial Transplant 1999; 14:2082-2084.
50. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, Elisaf M. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study [see comment]. J Clin Pathol 2004; 57:728-734.
51. Madhavan S, Stockwell D, Cohen H, Alderman MH. Renal function during antihypertensive treatment. Lancet 1995; 345:749-751.